Pseudotyped viruses are useful virological tools because of their safety and versatility. On the basis of a vesicular stomatitis virus (VSV) pseudotyped virus production system, we developed a pseudotyped virus-based neutralization assay against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in biosafety level 2 facilities. Compared with the binding antibody test, the neutralization assay could discriminate the protective agents from the antibody family. This protocol includes production and titration of the SARS-CoV-2 S pseudotyped virus and the neutralization assay based on it. Various types of samples targeting virus attachment and entry could be evaluated for their potency, including serum samples derived from animals and humans, monoclonal antibodies and fusion inhibitors (peptides or small molecules). If the pseudotyped virus stock has been prepared in advance, it will take 2 days to get the potency data for the candidate samples. Experience in handling cells is needed before implementing this protocol.

由于其安全性和多功能性，假型病毒是有用的病毒学工具。在水泡性口炎病毒 (VSV) 假型病毒生产系统的基础上，我们在生物安全 2 级设施中开发了一种针对严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 的基于假型病毒的中和试验。与结合抗体试验相比，中和试验可以将保护剂与抗体家族区分开来。该协议包括 SARS-CoV-2 S 伪型病毒的生产和滴定以及基于它的中和测定。可以评估针对病毒附着和进入的各种类型的样本的效力，包括来自动物和人类的血清样本、单克隆抗体和融合抑制剂（肽或小分子）。如果预先准备好假型病毒原液，则需要2天时间才能获得候选样本的效价数据。在实施此协议之前，需要有处理细胞的经验。